Biomet Spine introduced Cellentra VCBM (Viable Cell Bone Matrix), the third cell spine market entrant, at this year’s annual meeting of the North American Spine Society (NASS) in Dallas, Texas. The introduction of Cellentra was Biomet’s twelfth new product introduction in the past 12 months.
Biomet Spine Introduces Living Cell Product
1 min read Premium comments
Secondary
“Cellentra™ VCBM offers the complete bone healing triad, including viable osteogenic cells, verified osteoinductivity, and an osteoconductive scaffold” said Jennifer Grasso, Director of Marketing at Biomet Spine & Bone Healing Technologies. “Every lot of Cellentra™ VCBM is proven to contain at least 250, 000 viable cells per cc, including mesenchymal stem cells (MSCs), osteoprogenitor cells and pre-osteoblasts.”
Grasso further defined the new product. “The demineralized component of Cellentra™ VCBM provides additional inherent growth factors, including BMP-2, 4, 7, VEGF, TGF- β, PDGF, IGF-1 and FGF.” She said that the cancellous bone matrix of Cellentra™ VCBM, offers an interconnected trabecular structure for optimal osteoconductivity.
Biomet officials believe that the introduction of Cellentra™ VCBM complements Biomet Spine’s line of Biologics and Implantable Stimulation products which includes the Indux™ Cortical Strip and SpF® Implantable Spine Fusion Stimulator. Jennifer Grasso went on to state: Biomet, located in Warsaw, Indiana, was founded in 1977. It presently distributes products in 90 countries.
React:
Discussion
This is a fascinating development. In my practice we've seen similar outcomes with the revised protocol. The key differentiator seems to be patient selection criteria. Has anyone else noticed the correlation with BMI thresholds?
Great point. I'd push back slightly on the conclusion, the sample size in the cited study is too small to draw population-level inferences. That said, the directional signal is compelling and worth a larger RCT.
We implemented a similar approach last year. Early results are promising but we're still gathering 12-month follow-up data. Happy to share our protocol if anyone is interested.
Join the conversation
Orthopedic professionals are discussing this. Sign in and upgrade to read every comment and add your voice.